Understanding Cervical Cancer

Cervical cancer develops in the lining of the cervix, the opening between the vagina and uterus. Human papillomavirus (HPV) infection—primarily types 16 and 18—is the root cause in 99% of cases. Most women clear HPV naturally within 2–3 years; persistent infection with high-risk types leads to precancerous changes (dysplasia), progressing to cancer over 10–15 years. This slow progression makes cervical cancer uniquely preventable through vaccination and screening.

India bears the highest absolute cervical cancer burden globally: 97,921 new cases annually (GLOBOCAN 2022), with 42,090 deaths. This disparity stems from low screening coverage (especially rural areas), limited HPV vaccination access, and late-stage diagnosis. However, when caught early via Pap smear or HPV DNA testing, 5-year survival exceeds 90%; advanced cases treated with concurrent chemoradiation still achieve 50–60% 5-year survival.

The disease is highly treatable if detected in Stages I–IIA (80–90% cure rates with surgery or combined chemoradiation). Modern regimens—concurrent cisplatin chemoradiation, bevacizumab for advanced disease, and emerging immunotherapy (pembrolizumab)—have transformed outcomes. Most early-stage patients return to normal life within 3–6 months; fertility-sparing surgery is possible in select cases. HealOnco delivers these curative pathways as outpatient daycare, reducing hospitalization and treatment costs by 40–50%.

Cervical Cancer Subtypes

Signs and Symptoms

1. Post-coital bleeding: Vaginal bleeding or spotting after sexual intercourse; often first symptom in early cancer
2. Intermenstrual bleeding: Vaginal bleeding between periods; irregular menstrual cycles
3. Abnormal vaginal discharge: Watery, bloody, or foul-smelling discharge; may increase in volume
4. Pelvic or lower abdominal pain: Persistent pain during intercourse (dyspareunia) or non-menstrual cramping
5. Vaginal bleeding after menopause: Any vaginal bleeding in postmenopausal women warrants cervical evaluation
6. Heavier, prolonged menstrual periods: Increased menstrual flow or duration; lower abdominal heaviness
7. Rectal bleeding or painful bowel movements: If cancer invades rectum; may present with hematochezia or tenesmus
8. Urinary symptoms: Dysuria, hematuria, urinary frequency if bladder involved; lower urinary tract symptoms
9. Leg swelling or lymphedema: Unilateral leg edema from pelvic lymph node involvement; indicates advanced disease
10. Constitutional symptoms in advanced disease: Weight loss, fatigue, loss of appetite (Stage III–IV); often delayed presentation in rural India

If you notice any of these, see a doctor. In most cases the cause turns out to be benign, but the only way to be sure is an evaluation.

Risk Factors

Diagnostic Pathway

FIGO 2018 Staging & Prognosis

Treatment Modalities

Cold knife conization or LEEP (loop electrosurgical excision procedure)

Indications: Stage IA1 (microinvasive cancer); margins must be negative; therapeutic and diagnostic

Removes cervical cone-shaped specimen under colposcopic guidance; full thickness removed

Outcomes: Recurrence <1% if margins negative; 95–98% cure for IA1

Cost in India: ₹3,000–8,000 (government); ₹8,000–15,000 (private)

Radical trachelectomy (vaginal or abdominal approach)

Indications: Stage IA2 or IB1, nulliparous women desiring fertility; no lymph node metastases

Removes upper 1/3 to 1/2 of vagina, parametria, uterosacral ligaments, upper vaginal supports; uterus preserved; concurrent pelvic lymphadenectomy mandatory

Outcomes: Preserves fertility; ~80% achieve live births; recurrence rate 3–5%; obstetric complications (incompetent cervix) common

Cost in India: ₹60,000–120,000 (private gynecologic oncology center); not widely available in public sector

Radical hysterectomy (Wertheim or modified Okabayashi procedure)

Indications: Stage IA2, IB1, IIA1 (surgically fit patients, no para-aortic node involvement)

Removes uterus, cervix, parametria (lateral tissues to pelvic sidewall), upper 1–2 cm of vagina, and bilateral pelvic lymph nodes (pelvic lymphadenectomy)

Outcomes: 85–95% 5-year survival for IB1 (if no nodal metastases); complications: lymphedema (15–20%), bladder dysfunction (5%), bowel dysfunction (2–3%)

Cost in India: ₹80,000–150,000 (private); ₹20,000–50,000 (government)

Pelvic exenteration (anterior, posterior, or total)

Indications: Stage IVA (bladder/rectal invasion without distant mets); selected recurrent disease in previously irradiated pelvis

Anterior: removes uterus, cervix, bladder, distal ureters, proximal urethra; posterior: removes uterus, cervix, rectum, distal colon; total: removes both + creates ileal or colonic conduit

Outcomes: Only curative option for IVA; 5-year survival 30–50% with negative margins; high morbidity (fistulas, infection, sexual dysfunction)

Cost in India: ₹200,000–400,000 (specialized oncology centers only)

External Beam Radiation Therapy (EBRT)

Indications: All stages IB2 and beyond; adjuvant for high-risk early stage; extended field RT for para-aortic involvement

Linear accelerator delivers 3D conformal or intensity-modulated radiation therapy (IMRT); targets pelvic/para-aortic lymph nodes and cervix/parametria; dose 45–55 Gy in 25–28 fractions (180–200 cGy daily)

Side effects: Acute: diarrhea, cystitis, mucositis; late (>6 months): adhesions, vaginal stenosis (30–50%), small bowel obstruction (2–3%), rectal bleeding

Cost in India: ₹60,000–150,000 (IMRT/3D-CRT for full course); limited public sector availability

Brachytherapy (intracavitary)

Indications: Essential in all Stage IB2 and advanced cancers with concurrent chemoradiation; improves local control and survival by 15–25%

Radioactive source (Cesium-137, Iridium-192, or cobalt-60; increasingly high-dose-rate [HDR] afterloading) placed intrauterine (tandem) and lateral vaginal fornices (ovoids); delivers high local dose to point A (parametrial tissues at lateral cervix) while sparing rectum/bladder; dose 85 Gy equivalent dose at 2 Gy per fraction (EQD2 to point A)

Side effects: Acute: vaginal bleeding, discharge, cramping; late: vaginal stenosis (30–60%), rectovaginal fistula (<1%), sexual dysfunction

Cost in India: ₹20,000–50,000 per brachytherapy application (typically 4–5 applications); HDR more expensive than LDR

Cisplatin 40 mg/m2 IV weekly during EBRT (5–6 doses)

Indications: Standard for Stage IB2 and all advanced cervical cancer (IIA2 onwards); improves 5-year survival by 10–15% vs. RT alone

Cisplatin radiosensitizes tumor; impairs DNA repair; synergistic with EBRT and brachytherapy

Tolerability: Nephrotoxicity (pre-hydration required), ototoxicity, nausea/vomiting, hematologic toxicity; renal function must be monitored

Cost in India: Cisplatin ₹200–500 per vial (very cheap); weekly infusions during 5–6 week RT course; total cost ₹20,000–40,000

Carboplatin AUC 2 weekly (alternative for renal impairment)

Indications: Cisplatin-refractory or when creatinine >1.5 mg/dL; less effective than cisplatin but tolerated better in elderly/high-risk

Cross-links DNA; less nephrotoxic than cisplatin

Tolerability: Hematologic toxicity more common; nausea less severe

Cost in India: ₹1,500–3,000 per dose (more expensive than cisplatin)

Cisplatin 75 mg/m2 + Paclitaxel 175 mg/m2 IV every 3 weeks &#215; 6 cycles

Indications: Stage IVB (metastatic), recurrent disease, cisplatin + RT intolerant patients, palliative intent

Platinum-taxane doublet; cisplatin causes DNA crosslinks, paclitaxel stabilizes microtubules; synergistic activity

Response rate: 40–50% overall response; median OS 8–12 months in metastatic disease

Side effects: Hematologic (neutropenia, thrombocytopenia), peripheral neuropathy (20–30%, often cumulative), nephrotoxicity, alopecia, nausea

Cost in India: Cisplatin ₹300; paclitaxel ₹8,000–12,000 per dose (brand: Taxol, generic paclitaxel); 6 cycles ~₹100,000–150,000

Carboplatin AUC 5 + Paclitaxel 175 mg/m2 IV every 3 weeks &#215; 6 cycles

Indications: Cisplatin-ineligible (renal dysfunction, neuropathy), elderly, recurrent disease

Less nephrotoxic than cisplatin; carboplatin often preferred in frail patients

Response rate: 35–45% overall response

Side effects: Hematologic (thrombocytopenia more common), neuropathy, alopecia, nausea

Cost in India: Carboplatin ₹2,000–3,500 per dose; paclitaxel ₹8,000–12,000; 6 cycles ~₹120,000–180,000

Bevacizumab (Avastin, anti-VEGF monoclonal antibody)

Indications: GOG-240 trial (2013): recurrent/metastatic cervical cancer, combined with cisplatin + paclitaxel; improves OS by 3.7 months (median OS 17 vs. 13.3 months); now standard for fit patients with metastatic disease

Blocks vascular endothelial growth factor (VEGF); inhibits angiogenesis; reduces tumor blood supply

Response rate: Improved PFS from 8.5 to 12.6 months (GOG-240)

Toxicity: Hypertension (25–30%), proteinuria, bleeding (rare in cervical CA vs. lung Ca), GI perforation (<1%), thrombotic events (2–3%)

Cost in India: Bevacizumab 400 mg/vial: generic ‘Bevacibart’ ₹15,000–20,000 per dose; Avastin ₹35,000–50,000; 6 doses ~₹90,000–300,000 depending on brand

Pembrolizumab (Keytruda, anti-PD-1 checkpoint inhibitor)

Indications: KEYNOTE-826 trial (2022): recurrent/metastatic cervical cancer, PD-L1 combined positive score (CPS) ≥1; combined with cisplatin + paclitaxel as first-line; improves 18-month OS by 15% (OS 74% vs. 59%)

Blocks PD-1 checkpoint; enhances T-cell-mediated tumor recognition; synergistic with chemotherapy

Response rate: ~60% objective response rate (KEYNOTE-826); median PFS 12 months vs. 9 months without pembrolizumab

Toxicity: Immune-related adverse events (irAEs): colitis (1–2%), pneumonitis (1%), hepatitis (1–2%), endocrinopathy (thyroiditis 2–3%); manageable with steroids

Cost in India: Pembrolizumab (Keytruda) 100 mg: ₹80,000–120,000 per dose; 6 doses ~₹600,000, then maintenance; prohibitive for most Indian patients; generic pembrolizumab entry pending 2026

Cemiplimab (anti-PD-1 alternative)

Indications: Later EMPOWER-Cervical trial (2023): metastatic/recurrent, PD-L1+ ≥1%; second-line after chemoradiation failure

PD-1 inhibitor; similar to pembrolizumab

Response rate: ~30–40% in heavily pre-treated population

Toxicity: Similar irAEs as pembrolizumab

Cost in India: Not yet widely available in India; expected ₹90,000–150,000 per dose when available

Why Concurrent Chemoradiation Is Standard for Advanced Disease

In the 1990s, five landmark randomized trials (including GOG-120, GOG-123, RTOG 90-01, SWOG 8797, PIVER-IV) compared radiation alone to concurrent cisplatin chemotherapy + radiation in cervical cancer Stage IB2–IVA. Results were dramatic: concurrent chemoradiation reduced deaths by 30–50%, improving 5-year survival by 10–15% (e.g., GOG-120: 71% vs. 59% for stages II–IVA). Cisplatin acts as a radiosensitizer, enhancing DNA damage, preventing sublethal damage repair, and enabling reoxygenation of hypoxic tumor areas. This benefit holds across all advanced stages (IB2 through IVA), making it the global standard.

The concurrent approach (chemotherapy and radiation overlapping) outperforms sequential or adjuvant-only chemotherapy. Brachytherapy, delivered in 4–5 intracavitary applications during or shortly after EBRT completion, is non-negotiable: it delivers a tumoricidal dose to the cervix and parametria (85 Gy equivalent dose at 2 Gy/fraction to point A) while sparing bladder and rectum. Without brachytherapy, local control falls to 50–60% and 5-year survival drops 15–20%. The combination of EBRT + concurrent cisplatin + brachytherapy cures 60–80% of Stage IB2 patients and 30–50% of Stage III patients.

In India, concurrent chemoradiation is cost-effective compared to surgery (radical hysterectomy + lymphadenectomy): a full CRT course (45 Gy EBRT + 4 brachytherapy applications + 6 weekly cisplatin) costs ₹150,000–250,000 in private centers, vs. ₹80,000–150,000 for surgery. Public sector CRT is ₹30,000–60,000 but queues and limited brachytherapy availability delay treatment. Completed treatment within 56 days (8 weeks) maximizes outcomes; delays >8 weeks worsen local control by 1% per day. HealOnco’s daycare model prioritizes CRT completion within target timelines, reducing hospitalization burden.

A Day at HealOnco: Concurrent Chemoradiation Week 2

Treatment Costs in India (Private vs. Government)

Our Cervical Cancer Specialists

Our Centres

Modern Approach vs. Historical Treatment

Treatment Trade-offs

Surgery (radical hysterectomy) vs. Concurrent chemoradiation for Stage IB1 Surgery Pros: Single definitive intervention; short treatment duration (2–4 weeks recovery); No long-term radiation toxicity (vaginal stenosis, small bowel adhesions); Fertility preservation possible with trachelectomy (though rare complications like cervical insufficiency in 2–3%); Adjuvant RT only needed if adverse features (parametrial spread, LVSI); most IB1 with negative nodes avoid adjuvant RT Surgery Cons: Surgical morbidity: lymphedema (15–20%), bladder dysfunction (5%), bowel dysfunction (2–3%), perioperative mortality 0.5–1%; Prolonged hospital stay (5–7 days) vs. daycare chemoRT; Higher upfront cost in some settings; Sexual dysfunction from surgical nerve injury (>20% report dyspareunia) Chemort Pros: Non-invasive; daycare-feasible; shorter cumulative hospitalization (4–5 days total for brachytherapy); Avoids surgical morbidity; lower perioperative risk for elderly/comorbid; Cost lower in public sector (₹30,000–50,000 vs. surgery ₹25,000–45,000 govt, ₹80,000–150,000 private); Treats pelvic/para-aortic nodes in one field Chemort Cons: Prolonged treatment (5–6 weeks EBRT + brachytherapy); requires frequent visits (34–38 days total over 8 weeks); Acute toxicity: fatigue, diarrhea, cystitis, nausea (20–30% grade 2–3); Late toxicity: vaginal stenosis (30–50%), small bowel obstruction (2–3%), rectal bleeding (2–5%); Compromised fertility: ovarian suppression/failure in 60–70% premenopausal women; no pregnancy possible during/soon after RT (2-year recovery)

Bevacizumab-containing regimen vs. Chemotherapy alone for Stage IVB Bevacizumab Pros: Improved OS: median 17 months vs. 13.3 months (GOG-240); 30% improvement in 2-year survival; Combination addresses hypoxic tumor microenvironment (chemotherapy + anti-angiogenesis); Tolerable in most patients; hypertension manageable with antihypertensives Bevacizumab Cons: Cost: ₹15,000–50,000 per dose depending on brand; 6 doses = ₹90,000–300,000 (bevacizumab is 50–75% of total cost); Potential serious toxicity: GI perforation (rare in gynecologic but reported in ~1%), thrombosis, hemorrhage; Requires careful patient selection (no bowel obstruction, recent surgery, or uncontrolled HTN) Chemo Alone Pros: Lower cost (cisplatin + paclitaxel ₹100,000–150,000 vs. ₹200,000+ with bevacizumab); Fewer drug interactions; simpler adverse effect management; Established safety profile in older trials Chemo Alone Cons: Lower response rates and shorter survival (median OS 13.3 months); High recurrence/progression rate (median PFS 8.5 months)

Fertility preservation (trachelectomy ± adjuvant RT) vs. Radical hysterectomy in Stage IA2–IB1 Trachelectomy Pros: Uterus preserved; 70–80% of women desire pregnancy; live birth rate 60–80% in those attempting conception; Avoids long-term surgical morbidity (lymphedema, bladder dysfunction) vs. radical hysterectomy; Psychological benefit: retained fertility hope; reduced depression/anxiety in young women Trachelectomy Cons: Complex surgery; requires expert gynecologic oncologist (limited availability in India; mostly metro centers); Obstetric complications: cervical insufficiency (2–3%), preterm birth (15–20%), need for cervical cerclage; Mandatory pelvic lymphadenectomy (adds time, cost, lymphedema risk); If adjuvant RT needed (for adverse pathology), ovarian failure likely (60–70% amenorrhea/menopause); Recurrence rate 3–5% (slightly higher than hysterectomy 1–2%, though not statistically significant in small studies) Hysterectomy Pros: Established procedure; lower recurrence rate (1–2%); Avoids need for adjuvant RT in most IB1 with negative nodes/no LVSI; Widely available even in secondary care centers Hysterectomy Cons: Permanent loss of fertility; profound psychological impact in nulliparous women <30 years; Surgical morbidity unavoidable; long-term sexual dysfunction (dyspareunia, reduced desire) in 20–30%

Treatment Side Effects & Management

Read the full side effects guide for Cervical Cancer →

What Our Patients Say

Patient Stories

Video testimonials coming soon. We are working with patients who have completed treatment and are willing to share their journey on camera.

Frequently Asked Questions

Cervical Cancer Treatment in Top Cities

Cervical Cancer Treatment Cost by City

Cost pages for each city are being prepared and will link here once live. In the meantime, email info.healonco@gmail.com with your diagnosis details for a city-specific estimate.

Related Cancers We Treat

Supportive Care at HealOnco

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. onlinelibrary.wiley.com
2. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021;155(S1):28–44. [Indian context, ICMR recommendations] www.ncbi.nlm.nih.gov
3. GOG-120 (Gynecologic Oncology Group trial): Morris M, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137–1143. www.ncbi.nlm.nih.gov
4. GOG-240 (Bevacizumab trial): Tewari KS, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–743. www.ncbi.nlm.nih.gov
5. KEYNOTE-826 (Pembrolizumab trial): Colombo N, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2023;385(17):1856–1867. www.ncbi.nlm.nih.gov
6. WHO Cervical Cancer Elimination Initiative. Cervical cancer elimination as a public health issue. 2022. [Global strategy, India’s role] www.who.int
7. FIGO (International Federation of Gynecology and Obstetrics) 2018 Staging for Cervical Cancer. Bhatla N, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019;145(1):129–135. www.ncbi.nlm.nih.gov
8. National Cancer Registry Programme, Indian Council of Medical Research (ICMR). Cancer Incidence and Mortality across India 2012–2014. [India-specific epidemiology and burden] www.ncdirindia.org
9. Cervical cancer and HPV vaccination: CDC/WHO guidelines on vaccinating immunocompromised women, catch-up vaccination through age 45. www.cdc.gov
10. Schreuders PH, et al. Colorectal cancer screening outcomes in the European Union. Eur J Cancer. 2021; [global screening models adapted for cervical cancer context] pubmed.ncbi.nlm.nih.gov
11. National Comprehensive Cancer Network (NCCN) Guidelines for Cervical Cancer. Version 2.2025. [Definitive clinical practice guidelines] www.nccn.org
12. Ramirez PT, et al. Management of locally advanced cervical cancer. J Clin Oncol. 2020;38(25):2861–2876. [Modern multimodal approach] ascopubs.org